Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Importance: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness.
Objective: To test whether tocilizumab decreases mortality in this population.
Design, Setting, and Participants: The data for this study were derived from a multicenter cohort study of 4485 adults with COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with COVID-19 were categorized according to whether they received or did not receive tocilizumab in the first 2 days of admission to the ICU. Data were collected retrospectively until June 12, 2020. A Cox regression model with inverse probability weighting was used to adjust for confounding.
Exposures: Treatment with tocilizumab in the first 2 days of ICU admission.
Main Outcomes and Measures: Time to death, compared via hazard ratios (HRs), and 30-day mortality, compared via risk differences.
Results: Among the 3924 patients included in the analysis (2464 male [62.8%]; median age, 62 [interquartile range {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2 days of ICU admission. Patients treated with tocilizumab were younger (median age, 58 [IQR, 48-65] vs 63 [IQR, 52-72] years) and had a higher prevalence of hypoxemia on ICU admission (205 of 433 [47.3%] vs 1322 of 3491 [37.9%] with mechanical ventilation and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <200 mm Hg) than patients not treated with tocilizumab. After applying inverse probability weighting, baseline and severity-of-illness characteristics were well balanced between groups. A total of 1544 patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizumab. In the primary analysis, during a median follow-up of 27 (IQR, 14-37) days, patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92). The estimated 30-day mortality was 27.5% (95% CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1% (95% CI, 35.5%-38.7%) in the non-tocilizumab-treated patients (risk difference, 9.6%; 95% CI, 3.1%-16.0%).
Conclusions and Relevance: Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. However, the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.
| Errataetall: |
CommentIn: JAMA Intern Med. 2021 Jan 1;181(1):12-15. - PMID 33079980 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:181 |
|---|---|
| Enthalten in: |
JAMA internal medicine - 181(2021), 1 vom: 01. Jan., Seite 41-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Shruti [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 15.01.2021 Date Revised 10.06.2023 published: Print CommentIn: JAMA Intern Med. 2021 Jan 1;181(1):12-15. - PMID 33079980 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamainternmed.2020.6252 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316492698 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316492698 | ||
| 003 | DE-627 | ||
| 005 | 20231225161211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamainternmed.2020.6252 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316492698 | ||
| 035 | |a (NLM)33080002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Shruti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2021 | ||
| 500 | |a Date Revised 10.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: JAMA Intern Med. 2021 Jan 1;181(1):12-15. - PMID 33079980 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness | ||
| 520 | |a Objective: To test whether tocilizumab decreases mortality in this population | ||
| 520 | |a Design, Setting, and Participants: The data for this study were derived from a multicenter cohort study of 4485 adults with COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with COVID-19 were categorized according to whether they received or did not receive tocilizumab in the first 2 days of admission to the ICU. Data were collected retrospectively until June 12, 2020. A Cox regression model with inverse probability weighting was used to adjust for confounding | ||
| 520 | |a Exposures: Treatment with tocilizumab in the first 2 days of ICU admission | ||
| 520 | |a Main Outcomes and Measures: Time to death, compared via hazard ratios (HRs), and 30-day mortality, compared via risk differences | ||
| 520 | |a Results: Among the 3924 patients included in the analysis (2464 male [62.8%]; median age, 62 [interquartile range {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2 days of ICU admission. Patients treated with tocilizumab were younger (median age, 58 [IQR, 48-65] vs 63 [IQR, 52-72] years) and had a higher prevalence of hypoxemia on ICU admission (205 of 433 [47.3%] vs 1322 of 3491 [37.9%] with mechanical ventilation and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <200 mm Hg) than patients not treated with tocilizumab. After applying inverse probability weighting, baseline and severity-of-illness characteristics were well balanced between groups. A total of 1544 patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizumab. In the primary analysis, during a median follow-up of 27 (IQR, 14-37) days, patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92). The estimated 30-day mortality was 27.5% (95% CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1% (95% CI, 35.5%-38.7%) in the non-tocilizumab-treated patients (risk difference, 9.6%; 95% CI, 3.1%-16.0%) | ||
| 520 | |a Conclusions and Relevance: Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. However, the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Hayek, Salim S |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Mathews, Kusum S |e verfasserin |4 aut | |
| 700 | 1 | |a Melamed, Michal L |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, Samantha K |e verfasserin |4 aut | |
| 700 | 1 | |a Leonberg-Yoo, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Schenck, Edward J |e verfasserin |4 aut | |
| 700 | 1 | |a Radbel, Jared |e verfasserin |4 aut | |
| 700 | 1 | |a Reiser, Jochen |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Anip |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Finkel, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Mallappallil, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Faugno, Anthony J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Velez, Juan Carlos Q |e verfasserin |4 aut | |
| 700 | 1 | |a Shaefi, Shahzad |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Chirag R |e verfasserin |4 aut | |
| 700 | 1 | |a Charytan, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Athavale, Ambarish M |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Allon N |e verfasserin |4 aut | |
| 700 | 1 | |a Redfern, Roberta E |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Samuel A P |e verfasserin |4 aut | |
| 700 | 1 | |a Correa, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Pokharel, Kapil K |e verfasserin |4 aut | |
| 700 | 1 | |a Admon, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Donnelly, John P |e verfasserin |4 aut | |
| 700 | 1 | |a Gershengorn, Hayley B |e verfasserin |4 aut | |
| 700 | 1 | |a Douin, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Semler, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Hernán, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Leaf, David E |e verfasserin |4 aut | |
| 700 | 0 | |a STOP-COVID Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Walther, Carl P |e investigator |4 oth | |
| 700 | 1 | |a Anumudu, Samaya J |e investigator |4 oth | |
| 700 | 1 | |a Arunthamakun, Justin |e investigator |4 oth | |
| 700 | 1 | |a Kopecky, Kathleen F |e investigator |4 oth | |
| 700 | 1 | |a Milligan, Gregory P |e investigator |4 oth | |
| 700 | 1 | |a McCullough, Peter A |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Thuy-Duyen |e investigator |4 oth | |
| 700 | 1 | |a Shaefi, Shahzad |e investigator |4 oth | |
| 700 | 1 | |a Krajewski, Megan L |e investigator |4 oth | |
| 700 | 1 | |a Shankar, Sidharth |e investigator |4 oth | |
| 700 | 1 | |a Pannu, Ameeka |e investigator |4 oth | |
| 700 | 1 | |a Valencia, Juan D |e investigator |4 oth | |
| 700 | 1 | |a Waikar, Sushrut S |e investigator |4 oth | |
| 700 | 1 | |a Kibbelaar, Zoe A |e investigator |4 oth | |
| 700 | 1 | |a Athavale, Ambarish M |e investigator |4 oth | |
| 700 | 1 | |a Hart, Peter |e investigator |4 oth | |
| 700 | 1 | |a Upadhyay, Shristi |e investigator |4 oth | |
| 700 | 1 | |a Vohra, Ishaan |e investigator |4 oth | |
| 700 | 1 | |a Oyintayo, Ajiboye |e investigator |4 oth | |
| 700 | 1 | |a Green, Adam |e investigator |4 oth | |
| 700 | 1 | |a Rachoin, Jean-Sebastien |e investigator |4 oth | |
| 700 | 1 | |a Schorr, Christa A |e investigator |4 oth | |
| 700 | 1 | |a Shea, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Edmonston, Daniel L |e investigator |4 oth | |
| 700 | 1 | |a Mosher, Christopher L |e investigator |4 oth | |
| 700 | 1 | |a Shehata, Alexandre M |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Zaza |e investigator |4 oth | |
| 700 | 1 | |a Allusson, Valerie |e investigator |4 oth | |
| 700 | 1 | |a Bambrick-Santoyo, Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Bhatti, Noor Ul Aain |e investigator |4 oth | |
| 700 | 1 | |a Mehta, Bijal |e investigator |4 oth | |
| 700 | 1 | |a Williams, Aquino |e investigator |4 oth | |
| 700 | 1 | |a Brenner, Samantha K |e investigator |4 oth | |
| 700 | 1 | |a Walters, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Go, Ronaldo C |e investigator |4 oth | |
| 700 | 1 | |a Rose, Keith M |e investigator |4 oth | |
| 700 | 1 | |a Hernán, Miguel A |e investigator |4 oth | |
| 700 | 1 | |a Lisk, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Amy M |e investigator |4 oth | |
| 700 | 1 | |a Kim, Ethan C |e investigator |4 oth | |
| 700 | 1 | |a Chan, Lili |e investigator |4 oth | |
| 700 | 1 | |a Mathews, Kusum S |e investigator |4 oth | |
| 700 | 1 | |a Coca, Steven G |e investigator |4 oth | |
| 700 | 1 | |a Altman, Deena R |e investigator |4 oth | |
| 700 | 1 | |a Saha, Aparna |e investigator |4 oth | |
| 700 | 1 | |a Soh, Howard |e investigator |4 oth | |
| 700 | 1 | |a Wen, Huei Hsun |e investigator |4 oth | |
| 700 | 1 | |a Bose, Sonali |e investigator |4 oth | |
| 700 | 1 | |a Leven, Emily A |e investigator |4 oth | |
| 700 | 1 | |a Wang, Jing G |e investigator |4 oth | |
| 700 | 1 | |a Mosoyan, Gohar |e investigator |4 oth | |
| 700 | 1 | |a Nadkarni, Girish N |e investigator |4 oth | |
| 700 | 1 | |a Pattharanitima, Pattharawin |e investigator |4 oth | |
| 700 | 1 | |a Gallagher, Emily J |e investigator |4 oth | |
| 700 | 1 | |a Friedman, Allon N |e investigator |4 oth | |
| 700 | 1 | |a Guirguis, John |e investigator |4 oth | |
| 700 | 1 | |a Kapoor, Rajat |e investigator |4 oth | |
| 700 | 1 | |a Meshberger, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Kelly, Katherine J |e investigator |4 oth | |
| 700 | 1 | |a Parikh, Chirag R |e investigator |4 oth | |
| 700 | 1 | |a Garibaldi, Brian T |e investigator |4 oth | |
| 700 | 1 | |a Corona-Villalobos, Celia P |e investigator |4 oth | |
| 700 | 1 | |a Wen, Yumeng |e investigator |4 oth | |
| 700 | 1 | |a Menez, Steven |e investigator |4 oth | |
| 700 | 1 | |a Malik, Rubab F |e investigator |4 oth | |
| 700 | 1 | |a Cervantes, Carmen Elena |e investigator |4 oth | |
| 700 | 1 | |a Gautam, Samir C |e investigator |4 oth | |
| 700 | 1 | |a Mallappallil, Mary C |e investigator |4 oth | |
| 700 | 1 | |a Ouyang, Jie |e investigator |4 oth | |
| 700 | 1 | |a John, Sabu |e investigator |4 oth | |
| 700 | 1 | |a Yap, Ernie |e investigator |4 oth | |
| 700 | 1 | |a Melaku, Yohannes |e investigator |4 oth | |
| 700 | 1 | |a Mohamed, Ibrahim |e investigator |4 oth | |
| 700 | 1 | |a Bajracharya, Siddhartha |e investigator |4 oth | |
| 700 | 1 | |a Puri, Isha |e investigator |4 oth | |
| 700 | 1 | |a Thaxton, Mariah |e investigator |4 oth | |
| 700 | 1 | |a Bhattacharya, Jyotsna |e investigator |4 oth | |
| 700 | 1 | |a Wagner, John |e investigator |4 oth | |
| 700 | 1 | |a Boudourakis, Leon |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, H Bryant |e investigator |4 oth | |
| 700 | 1 | |a Ahoubim, Afshin |e investigator |4 oth | |
| 700 | 1 | |a Kashani, Kianoush |e investigator |4 oth | |
| 700 | 1 | |a Tehranian, Shahrzad |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Leslie F |e investigator |4 oth | |
| 700 | 1 | |a Sirganagari, Dheeraj Reddy |e investigator |4 oth | |
| 700 | 1 | |a Guru, Pramod K |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Yan |e investigator |4 oth | |
| 700 | 1 | |a Bergl, Paul A |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez, Jesus |e investigator |4 oth | |
| 700 | 1 | |a Shah, Jatan A |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Mrigank S |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Princy N |e investigator |4 oth | |
| 700 | 1 | |a Lazarous, Deepa G |e investigator |4 oth | |
| 700 | 1 | |a Kassaye, Seble G |e investigator |4 oth | |
| 700 | 1 | |a Melamed, Michal L |e investigator |4 oth | |
| 700 | 1 | |a Johns, Tanya S |e investigator |4 oth | |
| 700 | 1 | |a Mocerino, Ryan |e investigator |4 oth | |
| 700 | 1 | |a Prudhvi, Kalyan |e investigator |4 oth | |
| 700 | 1 | |a Zhu, Denzel |e investigator |4 oth | |
| 700 | 1 | |a Levy, Rebecca V |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA internal medicine |d 2013 |g 181(2021), 1 vom: 01. Jan., Seite 41-51 |w (DE-627)NLM220635021 |x 2168-6114 |7 nnns |
| 773 | 1 | 8 | |g volume:181 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:41-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamainternmed.2020.6252 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 181 |j 2021 |e 1 |b 01 |c 01 |h 41-51 | ||